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Abstract
Background: Acute rheumatic fever in New Zealand persists and is a barometer of equity as its burden almost
exclusively falls on Māori and Pacific Island populations. The primary objective of this study is to determine whether
an incentive programme will result in increased secondary prophylaxis injections over a one-year period compared
to a baseline period prior to the intervention.
Methods: The evaluation used a multiple baseline study to determine whether an incentive consisting of a mobile
phone and monthly “top-up” (for data/calls) resulted in increased injections, increased texts/calls with nurses,
reduced number of visits to get a successful injection, less medicine wasted, and increased nurse satisfaction.
Participants were 77 young people (aged 14–21) on an acute rheumatic fever registry in Waikato region, New
Zealand classified as either fully adherent (all injections received and no more than one late) or partially adherent
based on injections at baseline.
Results: There was a sharp increase in injections for intermittent patients post-intervention and then a slight
decrease overtime, while fully adherent patients maintained their high rate of injections (p = .003). A similar pattern
for nurse satisfaction emerged (p = .001). The number of calls/texts increased for all patients (p = .003). The number
of visits went down for partially adherent patients and up for fully adherent patients (p = .012). The overall
incremental cost-effectiveness was $989 per extra successful injection although costs increased sharply toward the
end of the intervention.
Conclusions: Incentivising secondary prophylaxis appears to have a strong impact for partially adherent patients,
particularly during the early periods following the initiation of the intervention. Enhancing communication with
patients who returned to care may result in more sustainable adherence.
Trial registration: Retrospectively registered: Australia New Zealand Clinical Trials Registry ACTRN12618001150235,
12 July 2018.
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Background
While acute rheumatic fever (RF) has declined to near
zero in most developed countries, it persists in New
Zealand (NZ) with 168 new hospitalizations in 2018
(3.6/100,000) [1]. RF is a barometer of equity and its
burden almost exclusively falls on Māori and Pacific
Island populations [2–5]. One study found that more
than 90% of diagnosed cases are in Māori and PI peoples
with a 30–40 times greater likelihood of being diagnosed
with RF than the European/other population [5]. RF is
associated with poverty and poor housing, including in-
adequate heating, poor insulation and crowded living
conditions [1, 3].
RF is an autoimmune reaction to untreated group A
streptococcal pharyngitis. RF results in swelling and in-
flammation of the heart, skin, brain and joints. Rheum-
atic heart disease (RHD) results from the inflammation
of a single episode or recurrent RF; it is damage to one
or more heart valves from stretching or scarring so the
valves do not work properly. This may result in a need
for value replacement surgery [1]. RHD has significant
impact on patients as it may result in premature death
in adults and is the primary cause of morbidity and mor-
tality for people who have had RF [6].
In New Zealand, individuals with an episode of RF re-
ceive secondary prophylaxis (SP); specifically an every
28-day injection of antibiotics (i.e., benzathine penicillin
G or ‘bicillin’) for a minimum of 10 years or until age 21
(whichever is longer) for those with no/mild rheumatic
heart disease [1]. SP prevents up to 97% of recurrence
[7, 8] and has also been shown to be the most cost ef-
fective strategy to prevent RHD [9].
Non-adherence to the injection schedule is a challenge
placing individuals at high risk of RF recurrence and/or
RHD [10–12]. Evidence suggests 77% of recurrence oc-
curs within the first 7 years post-initial episode of RF
[13]. The cost of non-adherence is large–60-70% of
those with RF who do not have monthly penicillin injec-
tions will go on to develop permanent heart valve dam-
age/RHD requiring costly surgery and increased health
burden [9].
Researchers have noted a number of factors associated
with SP adherence in developing countries and under-
served populations in developed nations [11, 12, 14–19].
In New Zealand, Barker and colleagues [20] identified
three levels of enablers and barriers to SP adherence
through an in-depth interview study of young people
(aged 14–21) with RF. First, access and resources include
district nurses (DNs) coming to patient’s work or home
to administer injections as an enabler. In contrast, lack
of income and getting time off work were barriers. In
particular, lack of income made access to mobile phones,
and hence getting in contact with DNs, a challenge.
Second, at the relational level, support from family and
friends was an enabler, while a lack of support was a bar-
rier. Third, at an individual level, high understanding of
RF and high personal responsibility were enablers of SP
adherence. In contrast, fear of and pain experienced with
injections were barriers.
Addressing this range of barriers for SP adherence can
be challenging for clinicians and researchers. Monetary
incentives (including vouchers or products) for address-
ing undesirable health care behaviours, including medi-
cation adherence in adolescent populations, has gained
popularity [21–23]. Monetary incentives and other
rewards-based programmes have a high level of accept-
ability for adolescents [24]. More importantly, there is
evidence that incentives produce positive health out-
comes for young people on such issues as substance
abuse [25], physical activity [26] and fruit and vegetable
consumption [27]. However, incentives are not without
challenges and some argue that they are paternalistic,
coercive, and undermine agency [28]. Further, incentives
may “crowd out” other motivators for health and other
behaviour such as altruism, social norms and individual
motivation [29, 30].
Monetary incentives are currently not used in clinical set-
tings in New Zealand; we also could not locate any litera-
ture demonstrating it use in other locations. Thus, the
primary objective of the project is to determine whether an
incentive programme will result in increased SP injections
for young people on an RF registry over a one-year period
compared to a baseline period prior to the intervention. In
addition, the analysis will calculate the incremental
cost-effectiveness ratio for delivering the intervention.
Secondary aims were to determine whether the following
desired effects were achieved post-intervention relative to
pre-intervention period: a) increased texts or phone calls
between DNs and patients; b) reduced number of visits to
deliver regular injections; c) reduced waste of medicine;
and d) increased DN satisfaction. The increase texts/calls is
desirable because it can reduce the number of no show ap-
pointments and save nurses time (i.e., reduced visits to de-
liver injections). The reduced wasted medicine is important
in the context of a world-wide shortage of bicillin from
2014 to 2016 [31]. DN satisfaction can have implications
for quality of relationships with patients which some studies
have shown to be important for adherence [17, 32].
The region where this study took place is the Waikato
District Health Board. The Waikato is the central region
of the North Island of New Zealand and includes a lar-
ger proportion of Māori and small portion of PI relative
to the whole of New Zealand. It is predominantly a rural
region with one moderate-sized city (Hamilton) where
the primary hospital is located. Rural regions are staffed
by DNs who cover large areas with small populations in
cities and towns and hence spend a lot of time in trans-
portation. The patients in the RF registry generally have
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low socio-economic backgrounds and a portion (about
20–25%) of these patients are highly mobile and difficult
to track and keep in touch with, particularly when they
do not have mobile phones.
Methods
Research design
The research design was a multiple baseline following par-
ticipants for a period of 15months (3months prior to
intervention and 12months after). In addition, the project
had participatory elements with a steering group formed
and composed of population health practitioners, district
nurses, Māori health experts and young people with RF.
The steering group collaborated on the development and
implementation of the intervention. The project was
retrospectively registered in the Australia New Zealand
Clinical Trials Registry (ACTRN12618001150235).
Participants
Patients (N = 85) between 14 and 21 years on the Wai-
kato RF Registry receiving SP were eligible for the inter-
vention. On the total 85 eligible, 77 agreed to
participate; 17 of these participants withdrew at various
stages due to being discharged (i.e., completing their in-
jections, n = 2) or moving to a new location where pro-
gress could not be tracked (n = 15).
The three-month period prior to the start of the inter-
vention was used to determine patient adherence status.
Patients who received all three injections and were late
on no more than one of the injections were classified as
fully adherent (n = 39). Patients who missed one or more
injections or were late on two or three injections were
classified as partially adherent (n = 38). We considered
using the existing registry for categorising patients’ ad-
herence status, but inconsistencies in data entry directed
us to use the baseline period. Specifically, data entry was
not up-to-date or did not reconcile with supervising
nurses’ knowledge about certain patients.
Given the imbalance in baseline (3 months) and
post-intervention (12 months), we broke the post-inter-
vention into four quarters to have comparable time pe-
riods. The following are the quarterly participation rates:
a) Pre: Fully adherent (39); Partially adherent (38); b)
Post 1st Quarter: Fully adherent (38); Partially adherent
(36); c) Post 2nd Quarter: Fully adherent (37); Partially
adherent (36); d) Post 3rd Quarter: Fully adherent (37);
Partially adherent (34); and e) Post 4th Quarter: Fully
adherent (34); Partially adherent (26). Key demographic
information for participants included the following: aver-
age age of 17.7 (SD = 2.00), 47% female, 82% Māori (in-
cluding 3 Cook Island Māori), 15% Pacific, and 3%
other. The average length of time on the registry was
43.64 months (SD = 30.74, median = 48). There was no
difference in the length of time on the registry for adher-
ence status.
At the end of the intervention, 10 patients (fully ad-
herent = 4; partially adherent = 6) completed an in-depth
interview to reflect on the intervention (these patients
also completed an interview at the start of the interven-
tion although it was a convenience sample). In addition,
seven district nurses (DN) who administered the inter-
vention and collected monthly data also completed an
in-depth interview about their experience. The inter-
views concentrated on the participants’ perspective of
the overall programme and concentrated on how com-
munication was impacted and the implementation of the
programme.
Intervention and procedures
The intervention was a new mobile phone at the begin-
ning of the intervention period and a top-up card ($20
for texts, calls, and data) when the patients received
their injection. Patients on contracted plans were offered
an alternative incentive of $20 in grocery vouchers
(n = 4). The phone and top-up were selected as the in-
centive because a) it was an appealing incentive; b) it ad-
dresses a social economic need for the high proportion
of young people with income challenges; and c) DNs
identify getting in contact with patients as a key
challenge.
Participants were recruited to the study by the DNs
through text, phone and word-of-mouth. Patients who
could not be reached by the DN were recruited by a
member of the research team. The research procedures
received ethical approval by the Northern A Health and
Disability Ethics Committee (16NTA33) and the Wai-
kato DHB Māori Research Review Committee. The base-
line period was conducted for three months prior to
consent. Once patients and/or parents provided written
consent (if participants < 16 years of age), the patients
then received their phone and then received the $20
top-ups after their regularly scheduled injection and data
was included for research. Multiple attempts were made
to contact patients after a missed injection and the
top-up was provided as soon as the patients received
their injections (even when late). The intent of the
programme was for the phone to lock out after 28 days
from the last top up (and injection), but unfortunately
this function was unable to be delivered upon by the
phone provider. As such the incentive in relation to
timeliness potentially lost the intended impact.
Measures
The primary outcome measure was the number of injec-
tions received in a three-month period. This was aver-
aged to three even though injections are received every
28 days in order to have a standard comparison across
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the quarters. The quarter was chosen for analysis as it
was the length of the baseline period. Secondary out-
come measures included number of in-person visits by
the DN prior to successful injection, number of texts or
phone calls placed by the DN to achieve the injection,
number of wasted injections (from taking medicine to
an appointment that was not kept by a patient), and DN
satisfaction with the injection process. The DN satisfac-
tion was measured on a single item ranging from 1 com-
pletely dissatisfied to 10 completely satisfied. All
measures were recorded by the DN for each injection
period (including date injection received and scheduled)
and given to a member of the research team who en-
tered the data. Data entry was checked by a second team
member and missing data was followed up by this team
member. Patients were not asked to provide any infor-
mation nor complete any forms during the regularly
scheduled visits.
Data analysis
Three types of data analysis were undertaken to address
the specific aims. For the first and second analyses, the
three-month period before the intervention was used as
a baseline, and the intervention arm was the
three-month increments after the intervention. First, to
address the outcomes, a repeated measures analysis of
variance was completed. The dependent variables were
the primary and secondary outcomes with time (pre-in-
tervention quarter, and the four quarters post interven-
tions) and injection status (fully adherent vs. partially
adherent) as the independent variables. All analysis was
completed with SPSS 25.0 (IBM, New York). Missing
data for two patients rendered the final analysis to 58
participants for the outcomes including all time periods.
We compared patients with complete data for all four
time periods and those who withdrew in the last quarter
(i.e., either transferred or completed injections after
three quarters) and found minimal differences; hence we
used the entire time period of the study. Second, to
address cost-effectiveness, a decision tree was built for
the incentives in increasing the adherence of injections
amongst Waikato young people with RF. The
cost-effectiveness analysis was from the perspective of
the public provider. Only direct costs to providers were
included, and costs to patients were not considered. The
direct costs to providers included costs of visit before in-
jection, the medicine, materials for injection, transport,
nurses’ time, phones, top-ups and phone calls from the
nurses. The unit costs and data sources of these re-
sources are outlined in Table 1. Incremental analysis was
performed in terms of incremental cost-effectiveness ra-
tio (ICER) by dividing the incremental costs with the in-
cremental injections by applying the intervention [33,
34]. The main outcome was cost per extra successful in-
jection. One-way sensitivity analysis was performed to
test the robustness of the results, by increasing or de-
creasing 20% of the unit costs or amount of medical re-
sources. Third, for the qualitative analysis to address the
participant and DN perspectives of the interventions,




Table 2 displays the means and standard deviations for
each of the outcome variables for the fully adherent and
partially adherent groups for each of the five time pe-
riods. For injections, there was a significant baseline
between-subjects effect [F(1,56) = 15.42, p < .001] and a
time X baseline status within-subjects effect [F(4,224) =
4.14, p = .003]. The between-subject effect illustrates that
those rated as fully adherent had a higher number of in-
jections than those in the partially adherent status. The
within-subject effect demonstrates that fully adherent
patients maintained their high rate of injections, while
partially adherent patients had a sharp increase after the
intervention then slightly decreased over time (i.e., a
Table 1 Unit costs and data sources
Cost elements Unit cost Data source
Visit before injection Transport and nurse’s time $103.50 per trip Waikato DHB
Successful visit for injection Transport and nurse’s time $103.50 per trip Waikato DHB
Cost per Penicillin injection Including injection materials $50 per injection Waikato DHB, Online Pharmaceutical
Schedule
Cost per Penicillin injection
wasted
Not including injection materials $31.5 per injection PHARMAC Online Pharmaceutical Schedule
Phone $399 per phone Waikato DHB
Top up or grocery voucher $20 after one injection Waikato DHB
Phone call from the nurse Nurse’s time for making phone
calls
$5 for a 5 mins phone call or
text
MECA salaries for community DNs
Note: overhead cost was included
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quadratic effect, [F(1,56) = 6.32, p = .015]). See Fig. 1 for
a display of the within-subjects effect.
Wasted injections
There were not any significant between-subjects or
within-subjects effects for wasted injections. Overall,
there was a 4.9% rate of wasted injections at baseline
and a combined rate of 4.4% post-intervention (with
3.2% the lowest in Quarter 1). There were no significant
differences between baseline and any post-intervention
period.
Visits
There was a significant baseline between-subjects effect
[F(1,56) = 5194.15, p < .001] and a time X baseline status
within-subjects effect [F(4,224) = 3.23, p = .013]. The
between-subject effect shows that those rated as fully
adherent had fewer visits with the DN than the partially
adherent group. However, the within-subject effect
qualifies this effect and reveals that the number of
patient visits with fully adherent patients increased
over time post-intervention, while the number of
visits with partially adherent patients decreased over
time such that by the end, fully adherent patients had
more visits than partially adherent patients (i.e., a lin-
ear effect, [F(1,56) = 6.79, p = .012]; see Fig. 1).
Texts/calls
There was a significant baseline between-subjects effect
[F(1,56) = 6.11, p = .016] and a time within-subjects
Table 2 Means and Standard Deviation of Outcome Variables
Time
Period
Injections Visits before Successful Injection Texts/Calls Wasted Injections DN Satisfaction
M SD M SD M SD M SD M SD
Fully adherent Pre 3.00 0.00 0.88 1.39 2.59 2.11 0.03 0.17 9.39 1.07
Q1 2.94 0.24 0.56 0.82 3.74 3.58 0.12 0.33 9.19 1.03
Q2 3.00 0.00 0.97 1.36 3.32 1.36 0.15 0.70 9.10 1.37
Q3 3.00 0.00 1.53 3.28 4.35 2.73 0.29 0.80 8.88 1.50
Q4 2.88 0.41 1.68 2.42 4.97 3.87 0.09 0.29 8.72 2.06
Partially adherent Pre 2.21 1.14 2.00 3.44 4.71 6.89 0.25 0.90 6.04 3.78
Q1 2.88 0.61 1.71 2.73 4.88 2.52 0.13 0.34 8.25 2.31
Q2 2.79 0.59 1.71 2.97 5.00 4.65 0.04 0.20 8.44 2.20
Q3 2.75 0.74 1.42 2.24 6.67 4.51 0.21 0.51 7.75 2.72
Q4 2.67 0.87 0.75 1.57 5.46 4.65 0.17 0.56 7.78 2.84
Fig. 1 Plots of means for outcome variables comparing fully adherent to partially adherent patients over five time periods. Note: Y axis refers to
number of injections, visits, texts/calls and wasted injection; DN satisfaction is rated on a scale from 0 to 10
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effect [F(4,224) = 2.98, p = .020]. The between-subjects
effect illustrates that more texts/calls were made to par-
tially adherent patients than fully adherent patients. The
within-subject effect demonstrates that the number of
texts/calls increased from baseline throughout the
study duration (i.e., a linear effect, [F(1,56) = 9.65, p
= .003]).
DN satisfaction
There was a significant baseline between-subjects ef-
fect [F(1,56) = 16.71, p < .001] and a time X baseline
status within-subjects effect [F(4,224) = 4.74, p = .001].
The between-subject effect illustrates that those rated
that DN satisfaction was higher with fully adherent
patients than with those in the partially adherent sta-
tus. The within-subject effect shows DN satisfaction
for fully adherent patients slightly decreased over
time, while it sharply increased for partially adherent
patients post-intervention and then slightly decreased over
time (i.e., a quadratic effect, [F(1,56) = 5.65, p = .021]; see
Fig. 1).
Incremental cost-effectiveness ratio
The intervention increased the number of successful in-
jections and total costs (Table 3). The ICER was rela-
tively small for the 1st quarter and the 2nd quarter after
intervention ($741 and $723 per extra successful injec-
tion), but almost doubled in the 3rd quarter ($1322 per
extra successful injection) and tripled in the 4th quarter
($2219 per extra successful injection). The overall ICER
for the 12-month period was $989 per extra successful
injection.
The sensitivity analyses (Table 4) show that the number
of visits before successful injections post-intervention has
the highest impact on the overall ICER. Increasing or de-
creasing 20% of the number of visits before successful in-
jections results in 14% increase or reduction in the costs
per extra successful injection. In contrast, the number of
phone calls and texts before injection or the unit cost of
phone call or text has a small impact on the ICER. In-
creasing or decreasing 20% of the number of phone calls
and texts increases or decreases only 2.7% of the costs per
extra successful injection.
Post-intervention interviews
Two themes were identified in the post-intervention in-
terviews: communication and implementation. Direct
quotes are used to illustrate these themes and included
names are pseudonyms. In regards to communication,
patients viewed the intervention as an enabler of effect-
ive communication with DNs. Patients noted that the
phone and top-up provided a resource they did not have
before:
It was helpful for the nurses to get a hold of me and
things … they did because I didn’t own a phone and
they always had to ring around to like all my family
member to see where I was. (Manaia, partially
adherent).
Yea yea, that’s the main thing; cause a lot of the times
I couldn’t text back like when they are there. And
they didn’t really call me much, so it was hard to get
a hold of them because I didn’t have credit… since
they gave me the top up I couldn’t not text back. I
Table 3 Medical resources and cost-effectiveness results between the pre-intervention and post-intervention
Results Q1 Q2 Q3 Q4 Overall
Number of eligible patients 74 73 71 60 77
Number of phones allocated† Post-intervention only 82 82 80 72 86
Number of visits before successful injection pre-intervention 107 109 106 81 403
Post-intervention 86 96 105 75 362
Number of phone calls/texts before successful injection pre-intervention 285 286 273 209 1053
Post-intervention 369 362 426 302 1459
Number of injections wasted pre-intervention 10 10 9 7 36
Post-intervention 7 8 15 7 37
Number of successful Injections pre-intervention 194 192 190 160 736
Post-intervention 212 212 201 165 790
Total costs pre-intervention $42,594 $42,499 $41,785 $34,209 $161,086
Post-intervention $55,928 $56,960 $56,324 $45,303 $214,514
Incremental Effectiveness (extra successful injections) 18 20 11 5 54
Incremental Cost $13,335 $14,461 $14,539 $11,094 $53,428
ICER (cost per extra successful injection) $741 $723 $1322 $2219 $989
† Patients were given a second phone if the first one was lost or broken; Note: Total costs include phone costs even though they were donated to the project
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didn’t have a reason not to text back. (Hohepa, par-
tially adherent).
About half of the nurses also agreed that it facilitated
good interaction with patients. For example, Memory
(DN) explained,
I was able to get a hold of the people because they had
a phone. Every month they could receive the texts. I
could arrange times to visit, and I caught them easier
because some of them don’t have the money to have a
phone. So they were hard to keep contact with because
with the phone numbers changed all the time or they
lost the phone or it was there brother’s phone or their
father’s phone or something.
The other half of the nurses thought that communi-
cation did not change. Tracey offered, “Yeah, in my
experience it made no real difference...They were dif-
ficult; some patients were difficult to contact prior to
the project. And those same patients are still difficult
to contact during and after the project.” Stephanie
stated, “Put it this way, it didn’t change the issues
that we had with contacting the patients even though
they had a phone and top-ups. We still had to chase
them.”
The second theme focused on implementation factors
that served as challenges to the programme’s effective-
ness. Patients described that oftentimes top-ups were
not available or they received a duplicate code that
would not work again:
Three times maybe that they couldn’t find it or something,
but I got in touch with the main doctor and she ended up
sending it through to me. Um yea it’s just that our hospital
is just unorganised (Maddison, fully adherent).
I think the last couple of weeks I never got my
top-ups…And I like, I keep telling them that. The nurses
never, they keep saying that they’ll give it, but they’re
only allowed to give one (Abel, partially adherent).
Maybe just make sure you have the top-ups every time,
because I haven’t got it in the last 5months…Oh they
weren’t too bad with like communicating, just with the
top-ups. They just were not good at all. It’s like they just
really didn’t care. (Hohepa, partially adherent).
These factors were not perceived as inhibitors to partici-
pation or receiving the injection; rather they were de-
scribed as a hassle and the focus of the ire was toward the
administrators of the programme not the nurses. Further,
our data suggests that it occurred in less than 10% of the
cases and a top-up was always provided.
The key implementation factor for many nurses was
that they disagreed with providing the incentive even if
patients received injections late. They felt it rewarded
negative behaviour.
I’m not the only one but it was like giving a reward for
negative behaviour. I know it was supposed to
Table 4 Results of one-way sensitivity analyses
Factors Incremental costs Overall ICER Difference compared to the baseline ICER
Amount of medical resources post-intervention
Number of phones allocated + 20% $59,732 $1106 11.8%
-20% $47,124 $873 −11.8%
Number of visits before injections + 20% $60,921 $1128 14.0%
−20% $45,935 $851 −14.0%
Number of calls or texts before injection + 20% $54,887 $1016 2.7%
−20% $51,969 $962 −2.7%
Number of injections wasted + 20% $53,661 $994 0.4%
−20% $53,195 $985 −0.4%
Unit costs of medical resources pre/post-intervention
Unit cost of phone + 20% $59,732 $1106 11.8%
−20% $47,124 $873 −11.8%
Unit cost of visit for injection + 20% $53,697 $994 0.5%
−20% $53,159 $984 −0.5%
Unit cost of Penicillin (not including injection materials) + 20% $53,974 $1000 1.0%
−20% $52,882 $979 −1.0%
Unit cost of top up/ grocery voucher + 20% $56,588 $1048 5.9%
−20% $50,268 $931 −5.9%
Unit cost of 5 min phone call or text + 20% $53,834 $997 0.8%
−20% $53,022 $982 −0.8%
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encourage the opposite behaviour…I didn’t think it was
a good idea. Well the negative behavior was they
wouldn’t come for their injections on time. So if they
came on time we would give them this top-up ok? But
even if they were still overdue, and didn’t come on time,
and they’re how many days overdue, and we still gave
them the top-up. (Stacey).
Yeah, I thought it was a negative that we were essen-
tially rewarding…there was no consequence for them.
They still received their top-up whether they received
their injection on time or not. So there was no real in-
centive for them to actively get in touch with us or be
proactive about having their injection on time because
they got it anyway; so they didn’t care. So they could
still have it, we could still be chasing them for two
weeks after the due date and they would still get their
top-up. So there was no, there was no incentive on
their part to be more compliant. (Tracey).
Nurses felt that the incentive would have been more
effective if they could withhold top-ups if late injections
were administered. As noted in the methods, the
intention was to have the phone be locked if they did
not receive their injection, but this feature did not work.
Discussion
The primary objective of this study was to increase the
number of SP injections for patients on a RF registry
and determine the ICER. Secondary outcomes were to
increase the number of texts/calls and reduce the num-
ber of visits between patients and DN; further desired
was a reduction in wasted injections and increase in DN
satisfaction. The findings generally supported the objec-
tives of the study although there were distinct differ-
ences for patients who were identified as fully adherent
versus partially adherent at baseline.
The incentives had an impact on injections, but not on the
number of wasted injections. The intervention had an im-
pact overall (p < .01) although this was qualified by a signifi-
cant time X baseline status interaction effect. Specifically, the
number of injections for fully adherent patients were by def-
inition high and generally maintained that level over the
course of the project. The number of injections for partially
adherent patients was moderate initially and had a sharp in-
crease post-intervention with levels slowly tapering off over
time, but still above the baseline levels. These results demon-
strate that incentives have a significant increase in desired
behaviour and consistent with prior research in other
contexts [21, 23, 26, 27]. The lack of impact on
wasted injections is likely because DNs did not take
medication to visits where they were not reasonably
sure that a patient would show up and hence there
were minimal situations to waste an injection. This may
be due to the worldwide shortage of bicillin that impacted
New Zealand at the beginning of the study [31].
The overall ICER for the 12-month period was $989
per extra successful injection, but this average was in-
flated by the costs in the second half of the intervention
period. Costs in the 1st and 2nd quarters were below
$800/incremental injection. The main reason for these
increased costs is the number of patients who trans-
ferred and thus there were not incremental increases in
injections over the baseline period. Further, to reduce
the costs per extra successful injection, we need to re-
duce the number of visits before successful injections,
and have more phone calls or texts to contact the pa-
tients to ensure successful visits for injections. If the
number of visits before a successful injection is reduced
by 50% and the number of phone calls or texts increases
by 50%, the overall ICER can be reduced by 28.2% (to
$710 per extra successful injection). It is important to
note that we included the cost of the phone in these cal-
culations even though they were donated by the phone
provider. Removing the phone costs results in an ICER
of $354 per extra successful injection.
These data do not allow us to make a concrete conclu-
sion about whether the intervention was cost-effective
because of the limited time frame although some con-
text can help with speculation and guiding future re-
search. Often with cost-effectiveness analysis, there is
desire to identify whether it impacts quality-adjusted life
year [34, 36]. This would require following people for a
significant amount of time to determine whether signifi-
cant adverse event occurred (e.g., recurrent RF, valve
surgery, death). A study of the mortality and cost of RF
and RHD in New Zealand found that 71% of the annual
$12 million (2009–2010 NZ dollars) in costs occurred
for individuals 30 or more years of age [6]. Further, 28%
of the total costs were for hospital admissions and 72%
were for heart valve surgery. If the intervention prevented
a later valve surgery, the current study’s ICER may be well
worth it given these costs. Additionally, there were an
average of 159 deaths each year with Māori and Pacific
peoples having a 5–10 times greater mortality rate [6].
Thus, there are health equity issues to be considered in
making these estimates. Unfortunately, we did not have
sufficient funding, nor is there a current infrastructure
(i.e., nurses are not required to make monthly entries to
the registry), to follow patients for a longer time period
even to determine even if some contracted RHD which is
the key aspect of the progression from RF to heart valve
surgery [13, 15]. Modelling this information from existing
data could be done and is beyond the scope of the current
study. Future research can be guided by these baseline
costs and ways to reduce the costs.
Positive results were found in the number of texts/
calls and visits. For all patients, the number of texts
and calls increased post-intervention as the phone en-
abled inexpensive contact between patients and DNs.
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This was corroborated by patient interviews and some
of the DN interviews. The results also illustrate that
the number of visits prior to injection decreased for
partially adherent patients, but actually increased for
fully adherent patients. Thus, the intervention had an
unintended consequence, and given the sensitivity
analysis, this consequence has detrimental impacts to
costs although not for outcomes. We speculate that
the reason for the increased visits was related to the
administration of the incentives although we cannot
state with certainty.
Finally, the intervention had a positive impact on DN
satisfaction working with partially adherent patients. The
relationship of DN satisfaction mirrored that of the
number of injections; specifically, satisfaction with fully
adherent patients was high and had a slight decline over
time, while for partially adherent patients satisfaction
was moderate and sharply increased post-intervention
and then had a slight decline, but remained above base-
line. Presumably, the positive impact on SP also resulted
in positive DN satisfaction as it made patients easier to
contact and hence reduced the job demands for the
nurses [37, 38]. However, there was slightly declining
DN satisfaction for fully adherent patients. The fully ad-
herent patients were initially high and DNs did not have
administrative responsibilities with them (i.e., data col-
lection and top ups). Further, the interviews with pa-
tients also noted some challenges with administration
related to the top-ups (although not a widespread prob-
lem). Hence, the DNs had more work for no increase in
patient outcomes. Thus, these factors may also have re-
sulted in declining DN satisfaction for fully adherent pa-
tients. These findings may have impacts on the
patient-nurse relationships and that potential could have
negative impacts on adherence given that some prior re-
search has found this relationship to be an important
enabler of SP [17, 32]. However, our own research with
the current patient population that the relationship with
the nurse is not the key enabler, but rather family sup-
port is most critical so future research is warranted [20].
The results of this study have some important prac-
tical implications for SP of RF in New Zealand. The
intervention had positive impacts for partially adherent
patients and actually brought some patients back to care
(based on interview responses and DN notes). Conserva-
tively, the DNs suggested (based on clinical notes) that
at least 16 patients were re-engaged to care when they
were thought to be non-adherent (and not just partially
adherent). Such re-engagement is very important given
that small doses of bicillin can be important at prevent-
ing recurrent RF [7, 8, 15]. It increased access to inex-
pensive communication and this is important as this
patient base has lower socio-economic status and often
do not have credit or data to contact their DN or reply
to texts as noted in the interviews with patients. Thus,
the intervention is potentially equity enhancing given
the inequitable distribution of income for this patient
population [39]. This is important in the context of po-
tential valvar surgery for patients who advance to
rheumatic heart disease due to lack of adherence to SP.
Unfortunately, the intervention only had minimal posi-
tive impacts for fully adherent patients. Specifically, it in-
creased texts and calls with the DN, but it also resulted in
more visits. Thus, this appears to be additional costs for
this patient population and perhaps only non-adherent pa-
tients should be incentivised. This incentive certainly
raises an ethical discussion about whether it is appropriate
to only incentivise patients who are not adherent and yet
the results suggest the positive outcomes are only for
non-adherent patients. These ethical discussions need to
be considered into the impact of incentives “crowding
out” internal motivations for behaviour [29, 30]. In fact,
some research demonstrates this crowding out exacer-
bates after the incentive is removed [29]; this effect was
beyond the study design as we did not collect data after
the incentive was stopped and can be addressed with fur-
ther research.
Beyond the simple incentive, there are key elements of
the administration that should be considered. First, the
DNs who participated in interviews suggest that provid-
ing top-ups to patients who were late at the very least
rewarded, and possibly even encouraged, negative behav-
iour. More importantly, DN engagement with patients
who return to care needs to be given careful consider-
ation. Unfortunately, 71% of the patients who transferred
or did not complete the study were from the partially
adherent group. In other words, the incentive brought
them back to care, but only maintained adherence for
6–9 months for some of them. This is a key opportunity
for DNs to (re)build a relationship of trust with the pa-
tients to encourage long-term adherence to SP. This rec-
ommendation is consistent with research demonstrating
that enhanced communication and incentives provide a
strong impact on health outcomes [25]. However, such
engagement also needs to be considered in the context
of a large workload for DNs. It also may suggest the
need for a larger scale study across District Health
Boards in New Zealand since this partially adherent
group is highly mobile and a linked approach to SP may
prove more effective.
This study is not without limitations. First, other than
patient interviews, we did not collect any data to explore
patients reasons for entering the programme or what
happened when they left. Thus, explanation of why the
programme worked is limited. Second, the study had a
fairly high (22%) attrition rate by the final quarter. This
attrition does raise concern about the sustainability of
the impacts of the incentives and hence the need to
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couple the intervention with a strong relationship with
the DNs. Third, we did not have a comparison/control
group and thus we cannot know for certain whether the
impacts are directly due to the intervention. Finally, re-
sources limited the length of the baseline period and any
post-intervention data collection. A longer baseline
period would better establish the predominant behaviour
of patients, while a post-incentive data collection would
help to determine if behaviour is maintained. Such data
would help make a stronger conclusion about the
cost-effectiveness of the intervention.
Conclusions
This study sought to determine if an incentive of a mo-
bile phone and monthly top-ups would increase SP in-
jections for patients on a RF registry. This incentive
demonstrated positive impacts for patients determined
to be partially adherent. It provided patients with a re-
source that facilitated effectively and timely communica-
tion with nurses. It can have positive short-term impacts
and potential long-terms impacts with effective engage-
ment by clinical staff. There is a need to effectively ad-
minister the programme to not inadvertently impact
nurse-patient relationships. Ethical considerations and
future research are needed to determine whether incen-
tives should be expanded to all RF patients, particularly
those that are fully adherent with their injections, and
whether late injections should be fully, partially or not
incentivised.
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